Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

In the phase III DELTA 1 and 2 studies, delgocitinib cream showed a rapid onset of efficacy – at week 16, half of the patients achieved a 75% improvement in HECSI. The results of the DELTA 3 extension study show that the therapeutic effects are stable in the long term and that the benefit-risk profile is good even with longer-term use. Delgocitinib cream is approved for all subtypes of chronic hand eczema in adults when topical corticosteroids are insufficient or unsuitable. It is an innovative treatment option that addresses an important treatment gap.